Research progress in endocrine clinical treatment of HR +/HER2 - metastatic breast cancer
10.3760/cma.j.cn121382-20220515-00510
- VernacularTitle:HR +/HER2 -晚期乳腺癌内分泌临床治疗的研究进展
- Author:
Shuling WANG
1
;
Chunfang HAO
;
Weidong LI
;
Zhongsheng TONG
Author Information
1. 天津医科大学肿瘤医院乳腺肿瘤内科，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，天津市"肿瘤防治"重点实验室，乳腺癌防治教育部重点实验室，天津 300060
- Keywords:
Hormone receptor HR-positive;
Human epidermal growth factor receptor HER2 negative;
Metastatic breast cancer;
Endocrine therapy;
Targeted therapy
- From:
International Journal of Biomedical Engineering
2022;45(5):430-436
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer, as a heterogeneous disease, has different molecular subtypes. The most common molecular subtype is hormone receptor positive (HR +). Endocrine therapy is the predominant treatment for this subtype. The main treatment modality for HR +/human epidermal growth factor receptor 2-negative (HER2 -) metastatic breast cancer (MBC) is novel targeted agents combined with endocrine therapy. In this review, researches in endocrine clinical treatment of HR +/HER2 - MBC was reviewed to provide a new targeted therapy, including CDK4/6 inhibitors combined with endocrine therapy, the debate between CDK4/6 inhibitors combined with endocrine therapy and chemotherapy, new directions of CDK4/6 inhibitor combination, exploration of multiple treatment strategies after CDK4/6 inhibitor therapy progresses, histone deacetylase inhibitor combined with endocrine therapy, PI3K/Akt/mTOR pathway targeting drugs in combination with endocrine therapy, polyadenosine diphosphate ribose polymerase (PARP) inhibitors for gBRCA1/2 mutated breast cancer, novel targeted drugs, and multi-target/multi-combination therapy model.
